SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Mauro Viganò, Giampaolo Mangia, Pietro Lampertico, Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy, Expert Opinion on Biological Therapy, 2014, 14, 7, 1019

    CrossRef

  2. 2
    Yutaka Tsutsumi, Reiki Ogasawara, Yusuke Kamihara, Shinichi Ito, Yoshiya Yamamoto, Junji Tanaka, Masahiro Asaka, Masahiro Imamura, Rituximab Administration and Reactivation of HBV, Hepatitis Research and Treatment, 2010, 2010, 1

    CrossRef

  3. 3
    Yutaka Tsutsumi, Yoshiya Yamamoto, Junji Tanaka, Masahiro Asaka, Masahiro Imamura, Nobuo Masauzi, Prevention of hepatitis B virus reactivation under rituximab therapy, Immunotherapy, 2009, 1, 6, 1053

    CrossRef

  4. 4
    Shobha Ramsubir, Makoto Yoshimitsu, Jeffrey A Medin, Anti-CD25 Targeted Killing of Bicistronically Transduced Cells: A Novel Safety Mechanism Against Retroviral Genotoxicity, Molecular Therapy, 2007,

    CrossRef

  5. 5
    Shobha Ramsubir, Makoto Yoshimitsu, Jeffrey A Medin, Anti-CD25 Targeted Killing of Bicistronically Transduced Cells: A Novel Safety Mechanism Against Retroviral Genotoxicity, Molecular Therapy, 2007,

    CrossRef

  6. 6
    Gerald Jäger, Franz Quehenberger, Werner Linkesch, Peter Neumeister, CHOP chemotherapy followed by Rituximab consolidation as first line treatment in patients with follicular lymphoma. Long-term follow-up of a phase 2 trial, European Journal of Haematology, 2007, 78, 5
  7. 7
    Qi Zhang, Guihua Chen, Xinyuan Liu, Qijun Qian, Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy, Cell Research, 2007, 17, 2, 89

    CrossRef

  8. 8
    Sercan Aksoy, Hakan Harputluoglu, Saadettin Kilickap, Didem Sener Dede, Omer Dizdar, Kadri Altundag, Ibrahim Barista, Rituximab-related viral infections in lymphoma patients, Leukemia & Lymphoma, 2007, 48, 7, 1307

    CrossRef

  9. 9
    Christina Nickenig, Martin Dreyling, Eva Hoster, Michael Pfreundschuh, Lorenz Trumper, Marcel Reiser, Hannes Wandt, Eva Lengfelder, Michael Unterhalt, Wolfgang Hiddemann, Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas, Cancer, 2006, 107, 5
  10. 10
    Winnie Yeo, Philip J. Johnson, Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy, Hepatology, 2006, 43, 2
  11. 11
    P. R. A. Taylor, J. M. White, R. J. Prescott, B. Angus, M. J. Galloway, G. H. Jackson, A. M. Lessells, H. H. Lucraft, G. P. Summerfield, S. J. Proctor, On Behalf Of The Scotland and Newca, The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial, Leukemia & Lymphoma, 2006, 47, 11, 2321

    CrossRef

  12. 12
    M. Stern, R. Herrmann, Overview of monoclonal antibodies in cancer therapy: present and promise, Critical Reviews in Oncology/Hematology, 2005, 54, 1, 11

    CrossRef

  13. 13
    Yutaka Tsutsumi, Hiroe Kanamori, Akio Mori, Junji Tanaka, Masahiro Asaka, Masahiro Imamura, Nobuo Masauzi, Reactivation of hepatitis B virus with rituximab, Expert Opinion on Drug Safety, 2005, 4, 3, 599

    CrossRef

  14. 14
    Bungo Saito, Eisuke Shiozawa, Toshiko Yamochi-Onizuka, Daisuke Adachi, Tsuyoshi Nakamaki, Shigeru Tomoyasu, Mitsuhiro Omine, Toshiyuki Mitsuya, Masafumi Takimoto, Hidekazu Ota, Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression, Pathology International, 2004, 54, 9
  15. 15
    Current Awareness in Hematological Oncology, Hematological Oncology, 2003, 21, 1
  16. 16
    Greg L Plosker, David P Figgitt, Rituximab, Drugs, 2003, 63, 8, 803

    CrossRef

  17. 17
    Greg L Plosker, David P Figgitt, Spotlight on Rituximab in Non-Hodgkin??s Lymphoma and Chronic Lymphocytic Leukemia1, American Journal of Cancer, 2003, 2, 4, 283

    CrossRef

  18. 18
    Axel Böhnke, Michael Wenger, Rituximab (Rituxan®),